NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), NATCO Pharma Limited, along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), are pleased to announce launch of the first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone (2) certain myelodysplastic syndromes and (3) mantle cell lymphoma following specific prior treatment. For more information refer to the prescribing information or other medical resources.

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

(C) 2022 Electronic News Publishing, source ENP Newswire